Skip to content
CFPS Research Archives

Aleniglipron

Human clinical Weight Loss & Metabolism 3 sources

Aleniglipron (GSBR-1290) is an investigational, orally-available, non-peptide small molecule agonist of the GLP-1 receptor. Research indicates it induces insulin release, promotes glucose clearance, reduces food intake, and decreases body weight, offering a potential once-daily oral alternative to injectable GLP-1 therapies for obesity and type 2 diabetes.

01Dosing reference

Amount
Investigational doses up to 240 mg/day
Frequency
Once daily
Cycle
Continuous daily use in clinical trials
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

GLP-1 Receptor Activation

Aleniglipron binds to and activates the glucagon-like peptide-1 (GLP-1) receptor as a non-peptide small molecule agonist.

02

Insulin Secretion & Gastric Emptying

Activation of the receptor stimulates glucose-dependent insulin release from the pancreas and slows gastric emptying.

03

Appetite Suppression & Weight Loss

These physiological changes lead to reduced food intake, improved glycemic control, and significant body weight reduction.

03Human evidence

Significant weight reduction in early clinical trials.

Phase 2 clinical trials (such as ACCESS II) evaluated aleniglipron in adults living with obesity, demonstrating positive topline data for weight loss and tolerability.

Improved glycemic control in Type 2 Diabetes.

Clinical studies (e.g., NCT07400588) are assessing its safety, tolerability, and efficacy in participants with Type 2 Diabetes Mellitus over extended periods.

04Preclinical evidence

Induction of insulin release and glucose clearance.

In vitro and animal models demonstrated that aleniglipron effectively activates the GLP-1 receptor, leading to improved glucose metabolism.

Reduction in food intake and body weight.

Preclinical obesity models showed significant decreases in food consumption and body weight following oral administration.

05What is known vs. unknown

Reasonably established
  • Aleniglipron is an orally bioavailable, non-peptide small molecule, unlike traditional peptide-based GLP-1 agonists.
  • It is designed for once-daily dosing, improving potential patient compliance compared to injectables.
  • Clinical trials are actively investigating its efficacy for both obesity and Type 2 Diabetes.
  • It mimics the effects of native GLP-1 by stimulating insulin secretion and reducing appetite.
Unknowns & limits
  • Long-term safety and cardiovascular outcomes in large human populations are still under investigation.
  • The exact long-term tolerability profile, particularly gastrointestinal side effects compared to injectable GLP-1s, requires further Phase 3 data.

06Safety & regulatory context

Regulatory statusAleniglipron is currently an investigational drug and is not yet FDA-approved. As a GLP-1 receptor agonist, its anticipated safety profile includes gastrointestinal side effects such as nausea, vomiting, and diarrhea, which are common in this class. Ongoing Phase 2 and Phase 3 clinical trials are closely monitoring its long-term safety, tolerability, and potential contraindications. It should only be used in approved clinical trial settings.

07Compared with Semaglutide

Aleniglipron vs. Semaglutide
Key difference
Aleniglipron is a non-peptide small molecule designed for oral administration, whereas Semaglutide is a peptide-based GLP-1 agonist primarily administered via subcutaneous injection (though an oral version exists, it has specific fasting requirements).
When researchers discuss each
Researchers discuss Semaglutide as the established standard for GLP-1 weight loss and diabetes management, while Aleniglipron is discussed as a next-generation oral alternative that may offer easier dosing and manufacturing scalability.

08Glossary

GLP-1 Receptor Agonist
A class of medications that mimic the GLP-1 hormone to stimulate insulin, lower blood sugar, and reduce appetite.
Small Molecule
A low molecular weight organic compound that can easily enter cells and is typically suitable for oral administration, unlike larger peptides.
Non-peptide
A compound that is not made of amino acids, making it less susceptible to degradation by digestive enzymes.

09Knowledge check

Q1What is the primary mechanism of action for Aleniglipron?
Q2How does Aleniglipron differ structurally from traditional GLP-1 medications like injectable Semaglutide?
Q3Which limitation about Aleniglipron's clinical evidence is explicitly stated in the dossier?
Q4How does the dossier describe the comparison between Aleniglipron and Semaglutide?
Q5Which statement best reflects Aleniglipron's safety and regulatory status as reported in the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism
Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism
Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism
Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.